BIOLINERX
Facebook
|
Twitter
|
Linkedin
| Careers | Contact Us
search

SEC Filings
Form 6-K
BIOLINERX LTD. filed this Form 6-K on 10/03/2018
Document Outline
Entire Document (792.7 KB)
Subdocument 1 - 6-K - 6-K
Page 1 - SECURITIES AND EXCHANGE COMMISSION
Page 2 - Amendment Agreement
Page 3 - N/A
Subdocument 2 - EX-10.1 - AMENDMENT AGREEMENT
Page 1 - Exhibit 10.1
Page 2 - IN WITNESS WHEREOF,
Page 3 - N/A
Subdocument 3 - EX-10.2 - STOCK PURCHASE AGREEMENT
Page 1 - Exhibit 10.2
Page 2 - DeliverySecurities Act
Page 3 - Voting and Stand-Still AgreementVoting and Stand-Still Agreement
Page 4 - ARTICLE 3
Page 5 - Material Adverse Change
Page 6 - Intellectual Property Rights
Page 7 - ARTICLE 4
Page 8 - Conditions to Biokine s Obligations to Close
Page 9 - Effect of Termination of the Agreement.
Page 10 - Notices
Page 11 - Assignment
Page 12 - Governing Law; Consent to Jurisdiction
Page 13 - In Witness Whereof,
Subdocument 4 - EX-10.3 - LOAN AGREEMENT
Page 1 - Exhibit 10.3
Page 2 - N/A
Page 3 - N/A
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - New Equipment
Page 9 - Advance Payment
Page 10 - Contractual Currency
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - Lender:
Page 25 - N/A
Page 26 - N/A
Page 27 - [Rest of page intentionally left blank]
Page 28 - SCHEDULE A
Page 29 - PART 1
Page 30 - SCHEDULE B
Page 31 - SCHEDULE C
Page 32 - SCHEDULE D
Page 33 - Jointly owned patents
Page 34 - N/A
Page 35 - N/A
Page 36 - SCHEDULE 1.27
Page 37 - SCHEDULE 1.28
Page 38 - SCHEDULE 1.40
Page 39 - SCHEDULE 3.5.1(xiv)
Page 40 - SCHEDULE 12.2.2
Page 41 - Duly executed by the parties on the date first set out on the first page of this Loan Agreement.
Subdocument 5 - EX-10.4 - WARRANT
Page 1 - Exhibit 10.4
Page 2 - Warrant ADS sADS sOrdinary Shares
Page 3 - Aggregate Exercise Price
Page 4 - Securities Act
Page 5 - Filing DateRegistration StatementSecurities ActRegistrable Shares
Page 6 - N/A
Page 7 - Conversion Shares
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - [Rest of page intentionally left blank]
Page 13 - IN WITNESS HEREOF
Page 14 - NOTICE OF EXERCISE
Page 15 - NOTICE OF CASHLESS EXERCISE
Subdocument 6 - EX-99.1 - PRESS RELEASE
Page 1 - Exhibit 99.1
Page 2 - Conference Call and Webcast Information
Page 3 - About BioLineRx


Interview with Philip Serlin, CEO
December 2016